Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

ETBX-011

Generic Name: ETBX-011

Drug Type: Biotech

Unique Ingredient Identifier: RP9RQ0SOM8

Overview

ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).

Background

ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1

Withdrawn

Posted: 2017/06/23

Sponsor:ImmunityBio, Inc.

ID:NCT03197571

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Phase 1

Withdrawn

Posted: 2017/06/05

Sponsor:ImmunityBio, Inc.

ID:NCT03175666

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1

Withdrawn

Posted: 2017/05/30

Sponsor:ImmunityBio, Inc.

ID:NCT03169764

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Phase 1

Withdrawn

Posted: 2017/05/30

Sponsor:ImmunityBio, Inc.

ID:NCT03169777

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Phase 1

Withdrawn

Posted: 2017/05/30

Sponsor:ImmunityBio, Inc.

ID:NCT03169738

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy